Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Arthur Kavanaugh; Christopher Ritchlin; Proton Rahman; Lluis Puig; Alice B Gottlieb; Shu Li; Yuhua Wang; Lenore Noonan; Carrie Brodmerkel; Michael Song; Alan M Mendelsohn; Iain B McInnes;

doi:10.1136/annrheumdis-2013-204741

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-204741 ◽

2014 ◽

Vol 73 (6) ◽

pp. 1000-1006 ◽

Cited By ~ 174

Author(s):

Arthur Kavanaugh ◽

Christopher Ritchlin ◽

Proton Rahman ◽

Lluis Puig ◽

Alice B Gottlieb ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Integrated Analysis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Radiographic Data

Download Full-text

Faculty Opinions recommendation of Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718283036.793491904 ◽

2014 ◽

Author(s):

Dafna Gladman ◽

Vinod Chandran

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Integrated Analysis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Radiographic Data

Download Full-text

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Download Full-text

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Arthritis Research & Therapy ◽

10.1186/s13075-020-2126-1 ◽

2020 ◽

Vol 22 (1) ◽

Author(s):

Philip Mease ◽

M. Elaine Husni ◽

Shelly Kafka ◽

Soumya D. Chakravarty ◽

Diane D. Harrison ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Disease Activity ◽

Radiographic Progression ◽

Controlled Trial ◽

Composite Index ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718257967.793494565 ◽

2014 ◽

Author(s):

Christian Jorgensen ◽

Yves-Marie Pers

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

THU0414 Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.1806 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 347.2-348 ◽

Cited By ~ 2

Author(s):

D. van der Heijde ◽

R. Landewé ◽

P. Mease ◽

I.B. McInnes ◽

P.G. Conaghan ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Radiographic Progression ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis

Arthritis & Rheumatology ◽

10.1002/art.42010 ◽

2021 ◽

Author(s):

Iain B. McInnes ◽

Proton Rahman ◽

Alice B. Gottlieb ◽

Elizabeth C. Hsia ◽

Alexa P. Kollmeier ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy ◽

Interleukin 23

Download Full-text

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(15)61134-5 ◽

2015 ◽

Vol 386 (9999) ◽

pp. 1137-1146 ◽

Cited By ~ 422

Author(s):

Iain B McInnes ◽

Philip J Mease ◽

Bruce Kirkham ◽

Arthur Kavanaugh ◽

Christopher T Ritchlin ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A ◽

Future 2

Download Full-text

Faculty Opinions recommendation of Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725609985.793524442 ◽

2016 ◽

Author(s):

Dafna Gladman

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A ◽

Future 2

Download Full-text

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-204655 ◽

2014 ◽

Vol 73 (6) ◽

pp. 990-999 ◽

Cited By ~ 364

Author(s):

Christopher Ritchlin ◽

Proton Rahman ◽

Arthur Kavanaugh ◽

Iain B McInnes ◽

Lluis Puig ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(09)79428-6 ◽

2010 ◽

Vol 2010 ◽

pp. 138-139

Author(s):

J. Weinberg

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Crossover Trial ◽

Interleukin 12 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text